AI to improve drug safety and personalize medicines
Precision Pharmacology and Pharmacovigilance: Leveraging AI to address drug safety knowledge gaps
This research uses artificial intelligence on medical records and biobanks to help make medications safer and more personalized for people taking prescription drugs.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11012094 on NIH RePORTER |
What this research studies
Researchers are combining artificial intelligence with electronic health records, biobanks, and clinical data to spot patterns behind adverse drug effects. They analyze messy, multimodal data and link clinical events to molecular and genetic information to understand why some patients have bad reactions. The team is building algorithms to detect and predict harmful drug responses and to handle missing or inconsistent data. The goal is tools that help doctors choose safer medications and flag potential drug-drug interactions before harm occurs.
Who could benefit from this research
Good fit: People taking prescription medications—especially those on multiple drugs or who have experienced adverse reactions—and patients whose medical records or biospecimens are in participating health systems or biobanks are the most relevant candidates.
Not a fit: People without accessible electronic health records, not enrolled in any biobank, or not taking prescription drugs may not see direct benefits from participating.
Why it matters
Potential benefit: If successful, this work could reduce dangerous side effects and help clinicians choose medicines that are safer and more effective for individual patients.
How similar studies have performed: Earlier studies using AI with EHRs and biobank data have shown promise in spotting drug safety signals, but this project expands and refines those methods to improve accuracy and biological understanding.
Where this research is happening
Los Angeles, United States
- Cedars-Sinai Medical Center — Los Angeles, United States (Active)
Researchers
- Principal investigator: Tatonetti, Nicholas P — Cedars-Sinai Medical Center
- Study coordinator: Tatonetti, Nicholas P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.